Back

Barclays rates Ligand Pharmaceuticals Overweight, sets $345 price target

Verifying
  • Barclays initiated coverage of Ligand Pharmaceuticals with an Overweight rating.
  • $345 represents Barclays’ price target, implying 15.37% upside from the current price.
  • Ligand Pharmaceuticals is expanding its royalty portfolio through cancer investments.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Barclays rates Ligand Pharmaceuticals Overweight, sets $345 price target - CoinPost Terminal